How Family and Friends Influence Breast Cancer Treatment Decisions
July 28, 2017
Where body fat is carried can predict cancer risk 
July 31, 2017
Show all

Coverage of Hepatitis C should be more balanced

Better coverage for hepatitis C treatment is needed.

One of the reasons hepatitis C drugs are not getting political attention is the statement “hepatitis C, a liver-damaging virus frequently contracted by injection-drug users” in the July 4 front-page article “One idea to counter high drug prices: Federal intervention.”

The Post has used similar statements multiple times in hepatitis C reporting in the past several years. While grammatically defensible, it leaves the reader with the impression that people with this disease are illegal drug users, which, for some people, would mean they are not as worthy of attention as other, more deserving patients. This is a completely false impression, as hepatitis C was present in the nation’s blood supply for years before it was identified.

My mother, who died of liver cancer last year, found out she had hepatitis C in her system 30 years after contracting it. She was not a drug user but simply someone who needed a blood transfusion during surgery. I would appreciate it if The Post could figure out some way to provide a more complete picture of how people contract hepatitis C. Legislators balancing limited resources need a more accurate public record.

Read full article: Coverage of Hepatitis C should be more balanced – The Washington Post

Read Full Article: Coverage of Hepatitis C should be more balanced – The Washington Post

The health and medical information on our website is not intended to take the place of advice or treatment from health care professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.

Comments are closed.